Document is current
Any future updates will be listed below
-
Authors
Joun, George L.
Kempe, Emma G. https://orcid.org/0009-0004-8470-6402
Chen, Brianna
Sterling, Jayden R.
Abbassi, Ramzi H. https://orcid.org/0000-0001-8007-4648
Friess, Dana https://orcid.org/0000-0003-2526-4451
Singleton, Matthew
Choudhury, Chandra
Marian, Oana C. https://orcid.org/0000-0001-5629-7884
du Preez, W. Daniel
Recasens, Ariadna
Clark, Teleri
Du, Tian Y. https://orcid.org/0000-0002-0674-361X
Low, Jason K. K. https://orcid.org/0000-0003-0862-0012
Kim, Hani
Yang, Pengyi https://orcid.org/0000-0003-1098-3138
Khor, Jasmine
Hoque, Monira
Indurthi, Dinesh C. https://orcid.org/0000-0001-8837-5883
Kuchibhotla, Mani
Palanisamy, Ranjith
Jorgensen, William T.
Montgomery, Andrew P.
Baker, Jennifer R.
Higginbottom, Sarah L.
Tomaskovic-Crook, Eva
Crook, Jeremy M. https://orcid.org/0000-0002-6415-1639
Loo, Lipin https://orcid.org/0000-0002-4112-1816
Day, Bryan W.
Neely, G. Gregory https://orcid.org/0000-0002-1957-9732
Guccione, Ernesto https://orcid.org/0000-0001-7764-5307
Johns, Terrance G.
Kassiou, Michael https://orcid.org/0000-0002-6655-0529
Feng, Yuchen
Harris, Lachlan
Don, Anthony S. https://orcid.org/0000-0003-1655-1184
Munoz, Lenka https://orcid.org/0000-0002-7625-5646
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (APP2003150)
Department of Health | National Health and Medical Research Council (APP1153961)
- License Information
-
More Information
Article History
Received: 17 October 2024
Accepted: 24 October 2025
First Online: 15 December 2025
Competing interests
: L.M., M.K. and W.T.J. are inventors on two patents related to the discovery and development of brain permeable microtubule-targeting agents, including CMPD1 and WJA88 used in this study (WO2016/119017; WO2019/148244). G.L.J., B.C., M.K. and L.M. are inventors on PCT/AU2024/050979 which covers the drug combinations described in this study for therapeutic use in cancer. E.G. received research funds from AZ and Prelude Therapeutics (for unrelated projects), EG is a cofounder and shareholder of Immunoa Pte.Ltd and cofounder shareholder, consultant, and advisory board member of Prometeo Therapeutics. Other authors declare no conflict of interest.
